IQVIA Holdings Inc. — Diagnostics & Research. Scored on the same transparent 7-signal model behind the daily rankings.
★
IQV
IQVIA Holdings Inc. · Diagnostics & Research
FCF$2.1bB
Rev+5.9%C+
D/E2.55D
P/E25.9xB
PEG0.83B+
70.6Score
$208.86$34.9B
1Y Target$229.63Analyst consensus · 19 analysts
5Y Target$289.90Compound horizon
10Y Target$371.80Long-dated conviction
FCF$2.1bTTMB
FCF $2.1b — solid, comfortably covers operations and capital return
Rev+5.9%TTM YoYC+
Revenue +5.9% — steady but below market-beating range
D/E2.55D
D/E 2.55 — most levered decile in Healthcare (≈95th pctile)
P/E25.9xB
P/E 25.9 — near the Healthcare median (≈60th pctile)
PEG0.83B+
PEG 0.83 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.6
Quality0.63
Growth0.72
Value0.78
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeMid-range
15% off the 12-month high
vs DCF fair value9% aboveest. fair value ~$191
Quality signals · context only
Gross profitability40% · A-gross profit ÷ total assets (Novy-Marx)
ROIC7.9% · C+return on invested capital — not score-weighted
Why now
Diagnostics & Research · market cap $34.9b. 15% off the 52-week high of $247.05. PEG 0.83 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $229.63 (implying +10% upside).
Moat
ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 153% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
D/E 2.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon
1-3 yr $229.63 (19-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $289.90 at ~7% CAGR — dividend + buyback compounding. 10 yr $371.80 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · IQV
Trend
-0.9 over 14 daily scores
From 71.5 (Jun 22) → 70.6 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · IQV
$
%
%
Shares to buy
9
Position size
$1,880
3.8% of portfolio
Stop price
$156.65
25% below $208.86
$ at risk if stopped
$469.94
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
IQVIA Holdings Inc. (IQV): score, valuation & FAQ
IQVIA Holdings Inc. (IQV) is a Diagnostics & Research company that scores 70.6 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (B+), while D/E (D) rate weaker. On valuation, IQV sits about 9% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is IQV a good stock to buy?
Bull Rankings scores IQV 70.6 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by PEG (B+). A score is a quantitative screen of IQVIA Holdings Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does IQV score 70.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). IQV earns its highest marks on PEG (B+), and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is IQV overvalued or undervalued?
Based on $208.86, IQV sits about 9% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 25.9x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in IQV?
D/E 2.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.